Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Solid Biosciences Inc. (Nasdaq: SLDB) announced participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, scheduled for April 24, 2023, at 2:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences Inc. (Nasdaq: SLDB) announced participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, scheduled for April 24, 2023, at 2:00 PM ET. The event will feature insights into the company's focus on developing genetic medicines for neuromuscular and cardiac diseases.
A live webcast will be accessible on the Company’s website, with a replay available afterward. Institutional investors interested in meetings during the conference can contact their Chardan representative. Solid Biosciences is known for programs like SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy, emphasizing a patient-centric approach to treatment.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was -1.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A replay will be available on the Company’s website following the event.
Institutional investors interested in meeting with management during the conference may reach out to their Chardan representative.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Solid Biosciences Media Contact:
Tim Palmer
Associate Director, Corporate Communications
607-760-4223
Tim@solidbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.